急性淋巴细胞白血病患者骨髓细胞中CCL2 mRNA的表达

Expression of chemokine receptor 2 mRNA in bone marrow cells of acute lymphocytic leukemia patients

背景:临床工作中希望能够根据骨髓CCL2表达对急性淋巴细胞白血病患者进行危险分层和预后判断。目的:观察急性淋巴细胞白血病患者骨髓细胞中CCL2 mRNA的表达情况。方法:初诊50例急性淋巴细胞白血病患者为实验组,30例非血液肿瘤患者为对照组。初诊急性淋巴细胞白血病患者化疗2个疗程后按疗效分为完全缓解组43例,未完全缓解组7例。实验抽取研究对象骨髓5mL,采用半定量聚合酶链反应法检测CCL2 mRNA表达。结果与结论:①初诊急性淋巴细胞白血病组CCL2 mRNA表达水平明显高于对照组(P<0.05);完全缓解组CCL2 mRNA水平明显低于未完全缓解组(P<0.01);完全缓解组治疗后CCL2 mRNA表达水平明显低于治疗前(P<0.01)。未完全缓解组治疗2个疗程后CCL2 mRNA表达水平无明显下降(P>0.05)。②前B-急性淋巴细胞白血病患者骨髓CCL2 mRNA表达水平明显高于普通B及T系急性淋巴细胞白血病患者(P<0.05)。初诊时白细胞≥50×109L-1急性淋巴细胞白血病患者CCL2 mRNA表达水平明显高于白细胞<10×109L-1及10×109L-1≤白细胞<50×109L-1组(P<0.05),10×109L-1≤白细胞<50×109L-1组明显高于白细胞<10×109L-1组(P<0.01)。结果表明急性淋巴细胞白血病患者骨髓细胞能分泌CCL2,骨髓CCL2 mRNA表达水平与患者初诊时的白细胞计数及免疫分型有一定的关系,在一定程度上能反映患者的近期疗效。

BACKGROUND： In clinical practice, the expression of chemokine receptor 2 （CCL2） in bone marrow cells is hoped to be used in hazardous classification and prognosis estimation of acute lymphocytic leukemia patients. OBJECTIVE： To investigate the expression of CCL2 mRNA in bone marrow cells of patients with acute lymphocytic leukemia. METHODS： Fifty patients with newly diagnosed ALL were selected as experimental group, and thirty patients without hematological tumor were taken as control group. After treatment, the experimental group was divided into complete remission （CR） group （43 cases） and incomplete remission group （7 cases） according to the efficacy. 5 mL bone marrow from each case was extracted in order to detect the CCL2 mRNA expression by semi-quantitative polymerase chain reaction. RESULTS AND CONCLUSION： CCL2 mRNA expression in the experimental group was significantly higher than that in the control group （P 0.05）. CCL2 mRNA expression in the CR group was significantly lower than that in the incomplete remission group （P〈0.01）. CCL2 mRNA expression in the CR group after treatment was decreased than before （P〈0.01）. CCL2 mRNA expression in the incomplete remission group before treatment was not obviously decreased compared with that after 2 courses of treatment （P 0.05）. CCL2 mRNA expression in acute lymphocytic leukemia patients with immune subtype pre-B was higher than with immune subtype common B and T （P 0.05）. CCL2 mRNA expression in patients with white blood cells≥50×10^9/L was higher than patients with white blood cells 10×10^9/L and 10×10^9/L≤ white blood cells 50×10^9/L （P 0.05）, the 10×10^9/L≤ white blood cells 50×10^9/L group was higher than the white blood cells 10×10^9/L group （P〈0.01）. It is indicated that the bone marrow of acute lymphocytic leukemia patients can secrete out CCL2, bone marrow levels of CCL2 mRNA are related to the count of white blood cells at diagrosis and the immune subtype. The levels of CCL2 mRNA can reflect the short short-term outcomes in some degree.